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E-cadherinAbstract This study focuses on curative effects of teniposide combining with semustine on patients
with neuroglioma and the influences on the expression of Twist and E-cadherin in tissue. Sixty-eight
patients with neuroglioma taking operation in our hospital were divided into two groups randomly.
Single radiotherapy was given to 34 patients in group A, and teniposide (VM-26) and semustine
(Me-CCUN) were added to radiotherapy for 34 patients in group B. Then, curative effects, survival
rate, living quality and adverse reaction rate after operation were compared between two groups.
Moreover, the difference in positive expression rate of Twist and E-cadherin before and after
treatment between two groups was analyzed by immunohistochemistry. Results: In group B, the
effective rate of treatment was 88.2%, and the disease control rate was 70.6%, higher than
52.9% and 32.4% in group A with statistical significance (P< 0.05). Moreover, the survival rate
in three years of group B was 44.1%, and the score of living quality was 67.11 ± 4.32, and also
higher than 23.5% and 63.79 ± 4.53 in group A with statistical significance (P< 0.05). However,
the difference between two groups in adverse reaction rate has no statistical significance (P> 0.05).
In addition, the difference in positive expression rate of Twist and E-cadherin between group A and
group B has no statistical significance before treatment (P> 0.05). After treatment, however, the
positive rate of Twist in group B is lower than that in group A, while the positive rate of
E-cadherin is higher. Both differences have statistical significance (P< 0.05). Chemotherapy of
VM-26 combining with Me-CCNU can inhibit Twist expression and improve the expression rate
of E-cadherin to help improving the curative effects and living quality and increasing survival rate.
 2016 The Authors. Production and Hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Neuroglioma, also called gliocytoma, is one of the common
malignant tumors in central nervous system at present.
Neuroglioma can make aggressive growth around brain tis-
sue, so complete radical treatment can be realized by single exci-
sion. Therefore, radiotherapy and chemotherapy are always
300 Y. Zhang et al.combined in clinical. However, the curative effects of different
chemotherapeutics are always greatly different for its various
varieties and combination with different drugs (Johnson et al.,
2014; Rogers, 2013). Therefore, the reasonable combination
with chemotherapeutics becomes the key to the postoperative
researches on patients with neuroglioma. As the current
research hotspots, Twist, the anti-apoptosis protein and E-
cadherin, the mark of epithelial–mesenchymal transition have
been generally accepted for their role playing in carcinogenesis
and transfer (Ding et al., 2012; Min et al., 2013). Currently,
there has no report on the influences of chemotherapeutics on
such protein expression. However, the curative effect will be
more persuasive if the role of chemotherapeutics can be
explained in aspect of protein level. Therefore, this work further
analyzed the difference in Twist and E-cadherin protein expres-
sion before and after chemotherapy when studying the curative
effects of teniposide with semustine on patients with neu-
roglioma. The research achievements are presented as follows:2. Materials and methods
2.1. General data
68 patients taking therapy in neurosurgery of our hospital from
March 2009 to June 2012 were selected. The inclusion criteria
are as follows: (1) taking craniotomy in our hospital and being
diagnosed by pathology with the complete follow-up materials
after operation; (2) age in 20–60 years old, Karnofsky life qual-
ity score (Karnofsky, KPS) P60, and survival period
P3 months; (3) no radiotherapy and chemotherapy contraindi-
cation and no severe injury in organs of heart, lung, liver and
kidney; and (4) marrow: white blood cell P4 * 109/L,
100 * 109/L blood platelet, and hemoglobin P80 * 109/L.
Patients were divided into group A of single radiotherapy and
group B of radiotherapy with chemotherapy with 34 patients
for each group. In group A, there were 18 male patients and
16 female patients in age of 26–53 years old with average age
of (38.5 ± 5.6) years old. Tumor site: 13 patients in frontal lobe,
9 patients in temporal lobe, 7 patients in occipital lobe and 5
patients in parietal lobe. Pathological grading: 8 patients in
grade II, 14 patients in grade III and 12 patients in grade IV.
In group B, there were 17 male patients and 17 female patients
in age of 26–56 years old with average year of (39.1 ± 5.5) years
old. Tumor site: 12 patients in frontal lobe, 10 patients in tem-
poral lobe, 8 patients in occipital lobe and 4 patients in parietal
lobe. Pathological grading: 9 patients in grade II, 13 patients in
grade III and 12 patients in grade IV. According to statistical
analysis, there is no statistical difference between two groups
in aspects of sex, age, tumor site, pathological grading, etc.
2.2. Therapeutic method
All the patients took operative treatment, and tumor tissue
was excised as much as possible without affecting the neuro-
logical function of patients. In this work, 34 patients took full
excision, 19 patients took sub-excision and 15 patients took
partial excision. In group A, patients took single radiotherapy
after operation with total dose of 50–60 Gy. Based on the
treatment in group B, patients in group B took combined
chemotherapy. The chemotherapy plan is as follows: the firstchemotherapy was conducted for patients 7–10 days after
radiotherapy with VM-26 by intravenous administration in
dose of 60–8060–80 mg/m2, d1-2 and with Me-CCUN by oral
administration in dose of 60–80 mg/m2, d3-4. The administra-
tion of both medicines was repeated every 8–12 weeks. Accord-
ing to the tolerance condition by patients, 2–7 courses can be
given. Before chemotherapy, 125 ml of 20% mannitol was
administrated by intravenous drip to improve the blood–brain
barrier permeability.
2.3. Immunohistochemistry
Surgery tissue was embedded by paraffin and sectioned (4 lm)
after being fixed with 10% formalin fixation. Then, immuno-
histochemical staining was conducted by SP method. Primary
antibodies of Twist polyclonal antibody and E-cadherin mon-
oclonal antibody and secondary antibodies were all purchased
from R&D Co. Immunohistochemical kit was purchased from
Shanghai Zemaisheng Biotechnology Co., Ltd.
2.4. Evaluation criteria
According to RECIST (Schramm et al., 2013) complete remis-
sion (CR): focus disappears for more than 4 weeks; partial
remission (PR): focus shrinks by P50% for 4 weeks; stable
disease (SD): focus shrinks by <50% or enlarges by <25%;
progression disease (PD): focus enlarges P25% or new focus
appears. Response rate (RR) = (CR+ PR)/total patients in
this group * 100%; disease control rate (DCR) = (CR+ PR
+ SD)/total patients in this group * 100%. After patients were
discharged from hospital, follow-up visit was conducted by
telephone, outpatient service, etc., and the living condition of
patients 1, 2 and 3 years after operation was recorded. Before
and after therapy, KPS was used to evaluate the living quality
of patients. In addition, drug safety was evaluated according to
the grading standard of adverse drug reaction regulated by
American National Cancer Institute.
2.4.1. Result judgment
Positive cell rates in 5 random views under 400 microscope
were calculated. Twist is positive after staining cell nucleus
or cytoplasm around cell nucleus. The score was counted as
follows: no color (score 0), light yellow (score 1), yellow (score
2) and brown (score 3); positive cell amount 1–10% (score 1),
11–25% (score 2), 26–50% (score 3) and above 50% (score 4).
By adding above two items, if the positive cell amount <1%
(), the score is 1–3 scores (+), 4–5 scores (++) and 6–7
scores (+++). E-cadherin is positive if the cytomembrane
and cytoplasm near cytomembrane are yellow or claybank,
and the positive rate can be calculated by the percentage of
staining positive cells accounting for total cells. The rate can
be recorded as follows: positive rate <10% (), 10–25%
(+), 26–50% (++) and >50% (+++). The glioma tissue
of patients was detected 1 year after operation and chemother-
apy, respectively.
2.5. Statistical method
SPSS statistical analysis software was used to do chi-square
test with patient number as numerical data and independent
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Figure 1 The survival curves of the two groups of patients.
Table 2 Comparison of KPS of patients in two groups before
and after treatment.
Groups n Before treatment After treatment t P
Group A 34 61.28 ± 4.86 63.79 ± 4.53 2.202 0.034
Group B 34 61.34 ± 4.92 67.11 ± 4.32 5.138 0.000
t 0.055 3.092
P 0.959 0.004
Figure 2 Twist the positive rate of two groups of patients before
and after treatment.
Patients treatment with neuroglioma 301or matching sample t-test with (x s) as numerical data. Then,
survival rates of both groups were compared with single-factor
survivorship curve (Kaplan–Meier) for Log rank test. When
P< 0.05, the difference has statistical significance.
3. Results
3.1. Comparison of recent curative effects
No death occurred during treatment in both groups. RR and
DCR distribution of group A are 32.4% and 52.9%, respec-
tively, lower than 70.6% and 88.2% in group B. The difference
has statistical significance (Table 1).
3.2. Survival condition
Kaplan–Meier method was used to calculate the survival con-
dition in both groups. The survival rates in three years of group
A and group B are 23.5% and 44.1%, respectively. Log rank
test shows that the difference between two groups has statistical
significance (X2 = 8.344, P= 0.003) (as shown in Fig. 1).
3.3. KPS score in both groups
Before treatment, the difference of KPS score between two
groups has no statistical significance. After treatment by differ-
ent schemes, KPS score of group B is significantly higher than
that of group A. Moreover, the difference has statistical signif-
icance (Table 2).
3.4. Adverse reaction
Two patients with I-grade myelosuppression in group A and 5
patients receiving I-grade bone marrow transplantation in
group B recovered without long-term marrow inhibition after
taking treatment with leukogenic drugs. In addition, 10
patients in group A and 14 patients in group B had different
degrees of digestive symptoms, including diarrhea, nausea
and emesis. After taking expectant treatment, these patients
turned better. Statistical analysis shows that the difference of
adverse reaction rate between two groups has no statistical sig-
nificance (X2 = 4.870, P= 0.300).
3.5. Twist expression condition in two groups before and after
treatment
Before treatment, the positive rate of Twist expression in two
groups has no significant difference (Z= 4.342, P= 0.463).
After treatment, however, the positive difference of Twist
expression in two groups has statistical significance
(Z= 8.852, P= 0.032) (as shown in Figs. 2 and 3).Table 1 Comparison treatment effect of two groups.
Groups n CR PR SD PD RR (%) DCR (%)
Group A 34 2 9 7 16 32.4 52.9
Group B 34 3 21 6 4 70.6 88.2
X2 9.950 10.204
P 0.041 0.0373.6. E-cadherin expression in two groups before and after
treatment
Before treatment, the positive rate of E-cadherin expression in
two groups has no significant difference (Z= 3.225,
P= 0.532). After treatment, however, the positive rate in
two groups has statistical significance (Z= 7.942,
P= 0.028) (as shown in Figs. 4 and 5).
4. Discussion
4.1. Current status of neuroglioma treatment
Statistical data show that the annual morbidity of neuroglioma
is 10–20/100 thousand people accounting for about 45–66% in
primary intracranial tumors. This disease primarily occurs to
people in age of 20–50 years old with 5-year survival rate lower
than 5% (Killela et al., 2013). However, some researches show
that the higher the malignant degree is, the stronger the ability
Figure 3 (A, C) is group A Twist protein expression before and after treatment, (B, D) is group B Twist protein expression before and
after treatment.
Figure 4 E-cadherin the positive rate of two groups of patients
before and after treatment.
302 Y. Zhang et al.of cytotoxin resistance, invasion transfer and proliferation
induced by tumor vessel will be because neuroglioma always
presents invasive growth and has no obvious demarcation in
normal brain tissue (O’Kane et al., 2013). Moreover, the char-
acteristics of ‘‘three highs and one low” that is, high morbidity,
high fatality rate, high recurrence rate and low cure rate are
much more significant. The technology of excising glioma by
neuro-navigation-guided or fluorescence-guided operationcan overcome problem of incomplete excision or injury to
brain tissue to some extent (Nong et al., 2013). However, for
patients with high malignant degree or obvious tissue invasion,
the curative effects of this technology are not satisfied, while
the curative effects of radiotherapy and chemicals treatment
are controversial. Therefore, it is significant to deeply under-
stand the mechanism of neuroglioma and make further
research on the influence factors on operative effects and post-
operative recurrence in view of molecule.
4.2. Application of VM-26 with Me-CCUN in neuroglioma
Traditional chemotherapeutics can be divided into (1) nitro-
soureas, including lomustine and carmustine, (2) natulane,
and (3) cisplatin. However, most of these drugs have following
problems: (1) restriction of drug entrance by blood brain barrier
only allows few lipid soluble drug passing; (2) tumor hetero-
geneity and tolerance; and (3) side effect of drug. References
reported that VM-26 with Me-CCUN can not only improve
drug effects, but also reduce adverse reaction (He et al., 2015).
As a main drug for DNA damage, Me-CCUN can make
DNA dead by combing it and interrupting the cell cycle. Also
as the drug for DNA damage, VM-26 plays a role in DNA
topoisomerase. Therefore, the combination of these two drugs
can not only reduce drug dose for each other and decrease the
adverse reaction, but also lower the drug resistance. According
to the research results in this work, the radiotherapy with med-
ical chemotherapy has obvious advantages compared with sin-
gle radiotherapy. For example, the effectiveness rate and disease
Figure 5 (A, C) is group A E-cadherin protein expression before and after treatment, (B, D) is group B E-cadherin protein expression
before and after treatment.
Patients treatment with neuroglioma 303control rate of former are 70.6%and 88.2%, respectively, which
are higher than those of later 32.4% and 52.9%. The difference
has statistical significance. The result is relatively consistent
with that of Smoll et al. (2013), by which the treatment measure
for 125 patients with neuroglioma is the same as that in this
work. The results in the study by Smoll show that the effective
rate is 73% and disease control rate is 90.2%. In addition, for
patients taking synchronous radiotherapy, the three-year sur-
vival rate is 44.1% and the living quality score is 67.11
± 4.32. For patients taking single radiotherapy, the three-
year survival rate is 23.5% and living quality score is 63.79
± 4.53. The difference between both is significant. Although
the adverse reaction rate for patients taking synchronous radio-
therapy is higher than that for patients taking single radiother-
apy, the statistical test shows that the difference between both
has no statistical significance. With expectant treatment, the
adverse symptoms of patients taking synchronous radiotherapy
have been relieved to some extent. For example, intravenous
injection of 5HT3 receptor antagonist can prevent emesis.
4.3. Twist, E-cadherin and neuroglioma
At present, more and more molecular markers related to
tumor are found, including Twist, E-cadherin, PTEN and
Ki-67 (Yang and Mao, 2013). Twist is also called as twist pro-
tein which has functions of adjusting embryonic development,
cell differentiation, organ growth, etc. Some researches show
that Twist has high expression in lung cancer, intestinal cancer,
breast cancer and tumor tissues. Nordfors et al. (2015) also
found in the study on 52 patients with neuroglioma and
non-tumor tissue of 30 patients that the Twist expression level
of former is significantly higher than that of later (Z= 8.51,
p< 0.01), and the expression level in higher-level glioma tissueis also higher than that in lower-level tissue (Z= 3.42,
p< 0.05). In addition, Khan verified that Twist can not only
improve the cell survival and its malignant transformation
by inhibiting p53 genes, but also induce epithelial–mesenchy-
mal transition (Khan et al., 2013). One of the specificity marks
of later is E-cadherin. The study shows that E-cadherin protein
mainly mediates interaction among cells, and it plays an
important role in cellular morphological change, signal trans-
duction and structural integrity of cells. E-cadherin expression
is abnormal, which can always cause loose cellular adhesion
and make tumor cells transfer or invade. For example,
Xiong et al. (2012) found in intestinal tumor research that E-
cadherin in tumor tissue is always in low expression, and this
phenomenon is negatively related to the tumor differentiation
degree, lymphatic metastasis and Ducks stages that is, patients
with low expression rate always have bad prognosis. Xiong
et al. (2014) found that Twist and E-cadherin have specific neg-
ative correlation (r= 0.57, p< 0.01) when studying the rela-
tionship between both for patients with neuroglioma. This
result helps us to judge the treatment prognosis of patients
with neuroglia.
4.4. Influences of chemotherapeutics on Twist and E-cadherin
Former researches show that the present biological marks are
mainly applied to the judgment of tumor diagnosis or treat-
ment prognosis. During the treatment, only a few researches
focus on the expression of tumor markers. The research on
Twist expression before and after radiotherapy or chemother-
apy of 54 patients with intestinal cancer shows that Twist
expression level is significantly lower than that of patients with
radiotherapy. However, Twist expression in both groups
before treatment has no difference (Fan et al., 2013).
304 Y. Zhang et al.5. Conclusion
According to the results in this work, the positive Twist rate of
patients taking synchronous chemotherapy is lower than that
of patients taking radiotherapy. Meanwhile, the positive
E-cadherin rate is higher than that in radiotherapy group. At
present, however, we cannot effectively explain why
chemotherapeutics have effects on protein expression. Even
though we can still prove that the combined chemotherapy is
beneficial to improve the survival rate and living quality of
patients after operation, it is also related to the inhibition or
high expression of protein.
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